Bulur Isil, Erdoğan Hilal Kaya, Karapınar Tekden, Saracoglu Zeynep Nurhan
Department of Dermatology and Venereology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Postepy Dermatol Alergol. 2017 Aug;34(4):334-338. doi: 10.5114/ada.2017.69313. Epub 2017 Aug 1.
Morphea, also referred to as localized scleroderma, is a rare fibrosing skin disorder of undetermined cause.
We report our single-center experience with morphea.
The study included 53 patients who were diagnosed with morphea by histopathology in our department between 2010 and 2015. Study data were collected retrospectively from the records of morphea patients.
The study included 53 patients (38 women, 15 men), and median age at onset was 39.0 (range: 8-85) years. Thirty (56.6%) patients had circumscribed morphea, 15 (28.3%) had generalized morphea, and 7 (13.2%) had linear morphea. One patient had mixed variant morphea (generalized, pansclerotic and linear morphea). ANA positivity was detected in 12 (22.6%) patients, but analysis for an association between the presence of ANA and morphea types, patients' characteristics did not reveal any significant associations. We did not observe any extracutaneous manifestations in patients during follow-up period. There were 2 of 53 patients who had concomitant autoimmune disorder including vitiligo and spondyloarthritis. Thirty (56.6%) patients received only topical treatment. The patients with clinical improvement who were treated with systemic therapy received methotrexate (26.4%), colchicine (9.4%), mycophenolate mofetil (5.7%) and prednisolone (1.9%).
Our results related to the demographic data of the patients and morphea types were consistent with the literature. On the other hand we observed that methotrexate was mostly used as an effective treatment option for generalized morphea.
硬斑病，也被称为局限性硬皮病，是一种病因不明的罕见纤维化皮肤病。
我们报告我们在硬斑病方面的单中心经验。
该研究纳入了2010年至2015年间在我们科室经组织病理学诊断为硬斑病的53例患者。研究数据从硬斑病患者的记录中回顾性收集。
该研究包括53例患者（38名女性，15名男性），发病时的中位年龄为39.0岁（范围：8 - 85岁）。30例（56.6%）患者患有局限性硬斑病，15例（28.3%）患有泛发性硬斑病，7例（13.2%）患有线状硬斑病。1例患者患有混合型硬斑病（泛发性、全硬化性和线状硬斑病）。12例（22.6%）患者检测到抗核抗体阳性，但对抗核抗体的存在与硬斑病类型、患者特征之间的关联分析未发现任何显著关联。在随访期间，我们未观察到患者有任何皮肤外表现。53例患者中有2例伴有自身免疫性疾病，包括白癜风和脊柱关节炎。30例（56.6%）患者仅接受了局部治疗。接受全身治疗且病情有临床改善的患者使用了甲氨蝶呤（26.4%）、秋水仙碱（9.4%）、霉酚酸酯（5.7%）和泼尼松龙（1.9%）。
我们关于患者人口统计学数据和硬斑病类型的结果与文献一致。另一方面，我们观察到甲氨蝶呤大多被用作泛发性硬斑病的有效治疗选择。
